The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

@article{Danysz2003TheNR,
  title={The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence},
  author={Wojciech Danysz and Chris G. Parsons},
  journal={International Journal of Geriatric Psychiatry},
  year={2003},
  volume={18}
}
  • W. Danysz, C. Parsons
  • Published 1 September 2003
  • Biology, Psychology
  • International Journal of Geriatric Psychiatry
There is increasing evidence for the involvement of glutamate‐mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD). We suggest that glutamate receptors of the N‐methyl‐D‐aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in this disorder. This continuous mild activation may lead to neuronal damage and impairment of synaptic plasticity (learning). It is likely that under such conditions Mg2+ ions, which block NMDA receptors under normal resting… 
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
TLDR
Findings suggest that inhibition of the NMDA‐R by memantine is sufficient to block excitotoxicity, while still allowing some degree of signalling, as well as restoring the number of neurons able to migrate out of the stressed microexplants.
Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias
The management of dementia has changed since the development of new antidementia drugs. The benefits observed in Alzheimer's disease (AD) with selective cholinergic transmission treatments are mainly
Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections
TLDR
Strong support for the clinical relevance of such interactions is provided by the NMDA receptor antagonist memantine, which offers an excellent tool to facilitate translational extrapolations from in vitro studies through in vivo animal experiments to its ultimate clinical utility.
The chemical biology of clinically tolerated NMDA receptor antagonists
Most neuroprotective drugs have failed in clinical trials because of side‐effects, causing normal brain function to become compromised. A case in point concerns antagonists of the
Memantine: a review of its use in Alzheimer's disease.
TLDR
In patients with mild to moderate Alzheimer's disease, data from three 24-week trials are equivocal, although meta-analyses indicate beneficial effects on global status and cognition, and Memantine is an effective pharmacotherapeutic agent, and currently the only approved option, for the treatment of moderate to severe Alzheimer's Disease.
Pharmacology of Acetylcholinesterase Inhibitors and N‐methyl‐d‐aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease
TLDR
Close examination of the pharmacology of the 2 compounds suggests that galantamine can augment memantine's glutamatergic noise suppression while simultaneously enhancing the physiologic glutamatorgic signal.
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
TLDR
Preclinical data have shown how these drugs act via two different, but interconnected, pathological pathways, and that their complementary activity may produce greater effects than either drug individually.
Effects of Memantine on Neuronal Structure and Conditioned Fear in the Tg2576 Mouse Model of Alzheimer's Disease
TLDR
Chronic memantine administration may have both neuroprotective and neurotoxic effects in a mouse model of AD, and memantine did not significantly improve behavioral deficits associated with genotype in a fear-conditioning paradigm at any dose.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).
TLDR
The data suggest that memantine, at therapeutically relevant concentrations, can protect against neuronal degeneration induced by beta-amyloid.
β‐Amyloid produces a delayed NMDA receptor‐ dependent reduction in synaptic transmission in rat hippocampus
TLDR
Results provide direct evidence that β-amyloid produced a delayed reduction in the function of glutamatergic synapses, probably as a result of an initial over-activation of the NMDA receptor-mediated component of transmission.
Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
TLDR
It is suggested that decreased glutamate transporter activiyt in AD is associated with increased excitotoxicity and neurodegeneration, supporting the possibility that abnormal functioning of this system might be involved in the pathogenesis of synaptic damage in AD.
Amyloid β Peptide (25–35) Inhibits Na+‐Dependent Glutamate Uptake in Rat Hippocampal Astrocyte Cultures
TLDR
In the present study, Aβ significantly inhibited l‐glutamate uptake in rat hippocampal astrocyte cultures and this inhibition was prevented by the antioxidant Trolox, leading to a revised excitotoxicity/free radical hypothesis of Aβ toxicity involvingAstrocytes.
Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease.
TLDR
It is suggested that decreased glutamate transporter activity in AD is associated with increased excitotoxicity and neurodegeneration, supporting the possibility that abnormal functioning of this system might be involved in the pathogenesis of synaptic damage in AD.
...
1
2
3
4
5
...